Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 28, 2026

Pebblebrook Hotel Trust Q4 Earnings Call Highlights

View original at finance.yahoo.com
Pebblebrook Hotel Trust Q4 Earnings Call Highlights Pebblebrook Hotel Trust logo Key Points Q4 results beat expectations: Same-property total RevPAR rose 2.9% and adjusted EBITDA increased 11.1% to $69.7 million, with adjusted EPS of $0.27, helped by stronger occupancy (+190 bps) and a 5.5% gain in non-room RevPAR…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The lower capital run rate is a tailwind that could support higher discretionary free cash flow for debt paydowns and repurchases

    80% confidence
  • Pebblebrook ended 2025 with stronger than expected fourth-quarter growth even as the government shutdown weighed on demand

    80% confidence
  • San Francisco RevPAR increased 37.9% in the quarter

    80% confidence
  • Most of the company's pace advantage was in transient demand, while group room nights were down 0.6% for the year

    80% confidence
  • January RevPAR increased 4.6% and would have been almost 7% but for Winter Storm Fern

    80% confidence
  • In December when there were zero conventions, Pebblebrook's San Francisco portfolio still delivered 16.2% RevPAR growth

    80% confidence
  • February was on pace for RevPAR growth of 15%+

    80% confidence
  • Weighted average interest cost of 4.1% is the lowest in the hotel lodging REIT sector

    80% confidence
  • Same-property hotel EBITDA was $2.2 million above the midpoint of the company's outlook

    80% confidence
  • Results reflected benefits from Pebblebrook's multi-year strategic reinvestment program and that several redeveloped properties are still ramping toward stabilization

    80% confidence
  • Pebblebrook may be reaching a favorable transition point

    80% confidence
  • Fourth-quarter total RevPAR in San Francisco increased more than 32%

    80% confidence
  • 2025 featured two very different storylines, with redeveloped resorts and urban recovery markets—especially San Francisco—driving growth, while Los Angeles and Washington, D.C. weighed on results due to unexpected events

    80% confidence
  • The company continued to see softness in government and government-related segments

    80% confidence
  • Full-year same-property expenses rose 3%, and excluding real estate tax and other credits from the prior year, total expense growth was 2.2%, with cost per occupied room basically flat

    80% confidence
  • The company does not expect additional business interruption income in 2026 for LaPlaya

    80% confidence
  • The company refinanced near-term maturities, extended maturities, increased the unencumbered asset base, and provided a fully funded path to address $350 million of convertible notes due December 2026

    80% confidence
  • Adjusted EBITDA was about $6 million above the midpoint

    80% confidence
  • Weather resiliency improvements at LaPlaya are complete and the property is fully restored following Hurricanes Helene and Milton

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com